WO2010022166A3 - Micro-arn (arnmi) et neurofibromatose de type 1 : un rôle en diagnostic et thérapie - Google Patents

Micro-arn (arnmi) et neurofibromatose de type 1 : un rôle en diagnostic et thérapie Download PDF

Info

Publication number
WO2010022166A3
WO2010022166A3 PCT/US2009/054336 US2009054336W WO2010022166A3 WO 2010022166 A3 WO2010022166 A3 WO 2010022166A3 US 2009054336 W US2009054336 W US 2009054336W WO 2010022166 A3 WO2010022166 A3 WO 2010022166A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
therapy
micro rna
neurofibromatosis type
methods
Prior art date
Application number
PCT/US2009/054336
Other languages
English (en)
Other versions
WO2010022166A2 (fr
Inventor
Xijie Yu
Janet M. Hock
Original Assignee
Maine Institute For Human Genetics And Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maine Institute For Human Genetics And Health filed Critical Maine Institute For Human Genetics And Health
Priority to AU2009283906A priority Critical patent/AU2009283906A1/en
Priority to EP09808780.2A priority patent/EP2326730B1/fr
Priority to CN2009801413494A priority patent/CN102186998A/zh
Priority to US13/059,862 priority patent/US8557786B2/en
Publication of WO2010022166A2 publication Critical patent/WO2010022166A2/fr
Publication of WO2010022166A3 publication Critical patent/WO2010022166A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des niveaux de certains micro-ARN qui sont modifiés dans des lignées cellulaires de NF1 et dans des lignées cellulaires de tumeur de NF1 par comparaison à des témoins qui ne sont pas NF1. Des procédés sont décrits, par exemple pour diagnostiquer des tumeurs de NF11 et NF1. Des procédés sont également décrits pour traiter NF1, un cancer associé à NF1 et des troubles cognitifs résultant de NF1.
PCT/US2009/054336 2008-08-19 2009-08-19 Micro-arn (arnmi) et neurofibromatose de type 1 : un rôle en diagnostic et thérapie WO2010022166A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2009283906A AU2009283906A1 (en) 2008-08-19 2009-08-19 Micro RNA and Neurofibromatosis Type 1 in diagnosis and therapy
EP09808780.2A EP2326730B1 (fr) 2008-08-19 2009-08-19 Micro-arn (arnmi) et neurofibromatose de type 1 : un rôle en diagnostic et thérapie
CN2009801413494A CN102186998A (zh) 2008-08-19 2009-08-19 微小rna和1型神经纤维瘤病在诊断和治疗中
US13/059,862 US8557786B2 (en) 2008-08-19 2009-08-19 Micro RNA (MiRNA) and neurofibromatosis type 1: a role in diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9015508P 2008-08-19 2008-08-19
US61/090,155 2008-08-19

Publications (2)

Publication Number Publication Date
WO2010022166A2 WO2010022166A2 (fr) 2010-02-25
WO2010022166A3 true WO2010022166A3 (fr) 2010-05-27

Family

ID=41707649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054336 WO2010022166A2 (fr) 2008-08-19 2009-08-19 Micro-arn (arnmi) et neurofibromatose de type 1 : un rôle en diagnostic et thérapie

Country Status (5)

Country Link
US (1) US8557786B2 (fr)
EP (1) EP2326730B1 (fr)
CN (1) CN102186998A (fr)
AU (1) AU2009283906A1 (fr)
WO (1) WO2010022166A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013034989A2 (fr) * 2011-09-07 2013-03-14 3-D Matrix, Ltd. Méthodes et dosages fondés sur des micro-arn et utilisables en relation avec un ostéosarcome
US11260072B2 (en) 2011-09-07 2022-03-01 3-D Matrix, Ltd. MicroRNA-based methods and assays for osteocarcinoma
US10905708B2 (en) 2011-09-07 2021-02-02 3-D Matrix, Ltd. MicroRNA-based methods and assays for osteocarcinoma
FR2984168B1 (fr) 2011-12-19 2019-07-05 Chanel Parfums Beaute Micro-rna pour leur utilisation dans la pigmentation
CN102925543A (zh) * 2011-12-27 2013-02-13 芮屈生物技术（上海）有限公司 白血病病变前期mRNA水平原位杂交检测试剂盒及检测方法和应用
EP2825209B1 (fr) * 2012-03-14 2018-08-29 University of Central Florida Research Foundation, Inc. Agents thérapeutiques pour la neurofibromatose et criblage de ceux-ci
CN104704122A (zh) * 2012-04-20 2015-06-10 艾珀特玛治疗公司 产热的miRNA调节剂
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
WO2014100252A1 (fr) * 2012-12-18 2014-06-26 University Of Washington Through Its Center For Commercialization Procédés et compositions permettant de moduler la maturation de l'arn
CN103045605B (zh) * 2012-12-26 2015-01-07 首都医科大学宣武医院 一种与脑血管狭窄有关的ⅰ型神经纤维瘤nf1基因突变核苷酸序列及其应用
JP6445516B2 (ja) 2013-03-14 2018-12-26 メディミューン，エルエルシー 組換えポリペプチドの生産
DK3155120T5 (en) * 2014-06-13 2019-01-28 Univ Wien Bodenkultur Procedures for diagnosing bone fractures and disorders
CN104745697B (zh) * 2015-03-24 2018-03-20 济南艾迪康医学检验中心有限公司 检测nf1基因第31‑34号全外显子的方法和引物
US10519442B2 (en) 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
CN106834442A (zh) * 2016-12-30 2017-06-13 王春庆 miR‑144‑3p在制备骨质疏松诊断标志物中的应用
CN107326076A (zh) * 2017-07-12 2017-11-07 北京赛尔维康生物医学科技有限公司 一种脊柱侧弯早期辅助检测试剂盒及其应用
EP3880310A1 (fr) * 2018-11-13 2021-09-22 Regulus Therapeutics Inc. Composés de microarn et méthodes de modulation de l'activité du mir-10b
WO2020118199A2 (fr) * 2018-12-07 2020-06-11 Yale Unversity Compositions et méthodes de traitement ou de prévention de nash, de nafld, du diabète, de l'athérosclérose et/ou de l'obésité
CN109536586B (zh) * 2018-12-25 2022-03-15 吉林大学 一种验证miRNA对于大鼠腺垂体GH分泌调控作用的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261218A1 (en) * 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
WO2007148235A2 (fr) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Acides nucléiques apparentés au cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850323A1 (fr) * 2004-11-12 2006-12-28 Asuragen, Inc. Procedes et compositions comprenant des molecules de micro-arn et des molecules d'inhibiteur de micro-arn
CN105902559A (zh) * 2005-08-01 2016-08-31 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CN101195657B (zh) * 2006-12-07 2011-06-15 中国医学科学院基础医学研究所 一个i型细胞因子受体样分子及其编码基因的应用
WO2008153692A2 (fr) * 2007-05-22 2008-12-18 The Brigham And Women's Hospital, Inc. Établissement de profil d'expression de micro arn du fluide cérébrospinal

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261218A1 (en) * 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
WO2007148235A2 (fr) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Acides nucléiques apparentés au cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
COSTA ET AL.: "Mechanism for the teaming deficits in a mouse model of neurofibromatosis type 1.", NATURE, 16 January 2002 (2002-01-16), pages 1 - 5, XP008135580 *
FERNER ET AL.: "Intemational Consensus Statement on Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis 1.", CANCER RESEARCH, vol. 62, 1 March 2002 (2002-03-01), pages 1573 - 1577, XP008135639 *
JOHNSON ET AL.: "RAS Is Regulated by the let-7 MicroRNA Family.", CELL, vol. 120, 11 March 2005 (2005-03-11), pages 635 - 647, XP002496112 *
MA ET AL.: "Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.", NATURE, vol. 449, 11 October 2007 (2007-10-11), pages 682 - 689, XP002547671 *
MILLER ET AL.: "Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues.", CANCER RES, vol. 66, no. 5, 1 March 2006 (2006-03-01), pages 2584 - 2591, XP008135579 *
RONCHETTI ET AL.: "An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.", BMC MEDICAL GENOMICS, vol. 1, no. 37, 13 August 2008 (2008-08-13), pages 1 - 9, XP021045829 *
TAKAMIZAWA ET AL.: "Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival.", CANCER RESEARCH, vol. 64, 1 June 2004 (2004-06-01), pages 3753 - 3756, XP002385720 *
YANG ET AL.: "Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1.haploinsufficient osteoclast functions.", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 116, no. 11, November 2006 (2006-11-01), pages 2880 - 2891, XP008135640 *

Also Published As

Publication number Publication date
EP2326730B1 (fr) 2014-03-19
AU2009283906A1 (en) 2010-02-25
CN102186998A (zh) 2011-09-14
US8557786B2 (en) 2013-10-15
US20110224286A1 (en) 2011-09-15
WO2010022166A2 (fr) 2010-02-25
EP2326730A4 (fr) 2011-08-03
EP2326730A2 (fr) 2011-06-01

Similar Documents

Publication Publication Date Title
WO2010022166A3 (fr) Micro-arn (arnmi) et neurofibromatose de type 1 : un rôle en diagnostic et thérapie
EP2322650A8 (fr) MicroARN et leurs utilisations
WO2016106400A3 (fr) Agents d'interférence arn pour la modulation du gène gst-pi
WO2006028655A3 (fr) Genes, compositions, kits, et methodes pour identification, evaluation, prevention et therapie du cancer de la prostate
WO2014081944A9 (fr) Molécules de liaison à domaine d'egfr et de c-met-fibronectine type iii
WO2008106646A3 (fr) Procédés et formulations pour une thérapie génique topique
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2009108866A3 (fr) Signatures en micro-arn associées à la cytogénétique et au pronostic dans la leucémie myéloïde aiguë (aml) et leurs utilisations
EP2322653A8 (fr) MicroARN et leurs utilisations
WO2009154835A3 (fr) Compositions et procédés liés à mir-16 et à la thérapie contre le cancer de la prostate
WO2010065787A3 (fr) Traitement de maladies liées à un gène suppresseur de tumeur par inhibition d'un transcrit antisens naturel du gène
EP3296406A3 (fr) Empreinte arnmi dans le diagnostic de cancer du poumon
WO2012149546A3 (fr) Induction du gène trail par petite molécule par des cellules normales et tumorales en tant que thérapie anticancéreuse
WO2005005601A8 (fr) Compositions et methodes de traitement et de diagnostic du cancer
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2008120098A3 (fr) Promédicaments peptidiques
WO2006026485A3 (fr) Modulation de l'expression de hif1 beta
CA2835730C (fr) Marqueurs moleculaires du cancer de la prostate
WO2008117314A3 (fr) Variants génétiques du chr2 et chr16 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2012006181A3 (fr) Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer
WO2009120712A3 (fr) Compositions et procédés pour diagnostiquer et traiter un mélanome
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2008092099A3 (fr) Compositions et procédés de traitement de malignités hématopoïétiques
WO2007062380A3 (fr) MODULATION DE L'EXPRESSION D’eIF4E-BP2

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980141349.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09808780

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009283906

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009808780

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009283906

Country of ref document: AU

Date of ref document: 20090819

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13059862

Country of ref document: US